Editorial Open Access Cardiovascular Pharmacology: Open Access Coenzyme Q10 for Cardiovascular Prevention

Cardiovascular disease including stroke is the leading cause of death and disability worldwide and is an enormous economic burden to our societies [1]. Based on the latest statistics released for heart and stroke disease, an estimated 83,600,000 adults in the United State (US) (>30%) have one form or another of Cardiovascular Disease (CVD), including more than 90 % with hypertension, 18 % with Coronary Heart Disease (CHD), close to 10 % with Myocardial Infarction (MI) and 8 % with stroke. The total direct and indirect cost in the US alone for treatment of CVD (hospitalization, drugs, home healthcare, etc.) and lots of productivity and morbidity is estimated at close to $315 billion US per year [2]. Thus prevention and early treatment of the major CV risk factors could provide huge savings in health care costs worldwide. Despite major advances in treatment of cardiovascular disease, the prevalence of hypertension, Ischemic Heart Disease (IHD) and stroke is still on the rise. Identifying optimal strategies for cardiovascula